cagrisema phase 3 results 2025 cagrilintide semaglutide combination obesity Updates in Medicine | in Adults With or Without Diabetes β REDEFINE 1 & 2 β’ π 2.4 mg + 2.4 mg once weekly β’ π β20.4% weight Another obesity contender just raised
Another obesity contender just raised the stakes. Novo Nordisk's CagriSema combination delivered around 20% mean weight loss in a large trial. The formula combines semaglutide with cagrilintide, giving the body multiple appetite control Novo Nordisk to present array of new portfolio data including studies with semaglutide and CagriSema, expanding evidence in obesity and diabetes care at ADA 2025 Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination CagrilintideSemaglutide in Adults with Overweight or Obesity and Type 2 Diabetes New England Journal of Medicine Cagrilintidesemaglutide (CagriSema) as an add on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double blind, placebo controlled, multicentre, phase 3 study The Lancet HCPLive CagriSema, a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved superior weight loss to placebo in adults with obesity or overweight and T2D in the Phase
Pay in 4 interest-free payments of $6.97 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 2 - Aug 7


01022-6/asset/3f55ea20-b36b-4e11-88e9-940a60e8677e/main.assets/gr2_lrg.jpg)